soul trial semaglutide Presented at #ACC25: Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral (14 mg) was associated with a lower risk of cardiovascular events than placebo SOUL (Semaglutide cardiOvascular oUtcomes triaL)
Pay in 4 interest-free payments of $7.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31






















